Girentuximab Biosimilar Radiolabelled Antibody (CAIX) for Research

Cat No.: GMP-Bios-ab-245

Pre-Made Girentuximab biosimilar, Whole mAb Radiolabelled, Anti-CA9/CA-IX Antibody: Anti-CAIX/MN therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Girentuximab (trade name Rencarex) is a chimeric IgG1 monoclonal antibody to carbonic anhydrase IX (CAIX).[1] CAIX is expressed on the surface of most renal cancer cells and is hypothesized to be on the surface of other tumor cells. It is investigational agent in clinical trials for renal cell carcinoma. Its development was suspended as a "naked" or unconjugated antibody during phase III trials due to efficacy.

Order Information

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. →
Catalog No. Package Price(In USD)
GMP-Bios-ab-245-1mg 1mg
GMP-Bios-ab-245-10mg 10mg
GMP-Bios-ab-245-100mg 100mg
GMP-Bios-ab-245-xmg ≥100mg



Product Details

Products Name (INN Index) Pre-Made Girentuximab biosimilar, Whole mAb Radiolabelled, Anti-CA9/CA-IX Antibody: Anti-CAIX/MN therapeutic antibody
INN Name Girentuximab
TargetCA-IX
FormatWhole mAb Radiolabelled
DerivationChimeric (Mouse/Human)
Species ReactivityHuman
CH1 IsotypeIgG1
VD LCKappa
Highest_Clin_Trial (Jan '20)Phase-III
Est. StatusDiscontinued
100% SI StructureNone
99% SI StructureNone
95-98% SI StructureNone
Year Proposed2009
Year Recommended2010
CompaniesCentocor Inc;Heidelberg Pharma AG
Conditions Approvedna
Conditions Activena
Conditions DiscontinuedRenal cancer
Development Techna



About target - CA9

1. Protein Carbonic anhydrase 9

2. Gene CA9

3. Organism Homo sapiens (Human)

Function
Reversible hydration of carbon dioxide. Participates in pH regulation. May be involved in the control of cell proliferation and transformation. Appears to be a novel specific biomarker for a cervical neoplasia.

Catalytic activity
H+ + hydrogencarbonate = CO2 + H2O
EC:4.2.1.1
Source: Rhea.

Cofactor
Zn2+

Activity regulation
Inhibited by coumarins, saccharin, sulfonamide derivatives such as acetazolamide (AZA) and Foscarnet (phosphonoformate trisodium salt).

pH dependence
Optimum pH is 6.5.